Following a chemical screen, researchers at the laboratory characterized two molecules that behave
in vitro as antagonists of the CK2α/CK2ß interaction. They disrupt CK2-dependent signaling in cultured cells and lead to inhibition of proliferation and induction of apoptosis of mammary cancer cells. Selective inhibition of the CK2α/CK2ß interaction therefore represents an innovative approach that offers the possibility of pharmacologically testing the importance of this interaction in tumor growth processes.